Loading...
•
Jun 30, 2024
Longeveron Q2 2024 Earnings Report
Announced second quarter 2024 financial results and provided a business update.
Key Takeaways
Longeveron Inc. reported on the progress of its investigational cellular therapy candidate, Lomecel-B™, for Alzheimer’s disease and Hypoplastic Left Heart Syndrome (HLHS). The U.S. FDA granted Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation for the treatment of mild Alzheimer’s disease. The company believes it has sufficient capital to fund operations through the fourth quarter of 2025.
Advanced Lomecel-B™ as a potential treatment for Alzheimer’s disease and Hypoplastic Left Heart Syndrome (HLHS).
Received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the FDA for Lomecel-B™ in treating mild Alzheimer’s disease.
Observed strong interest and support for the HLHS ELPIS II Phase 2b clinical trial, which has achieved 70% enrollment.
Capital sufficient to fund the Company through the fourth quarter of 2025.
Revenue by Segment
Forward Guidance
Longeveron believes it has sufficient capital to fund the Company through the fourth quarter of 2025.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...